For example, GLP-1 receptor agonists like semaglutide have become popular for their weight loss and glycemic benefits
Unlike treatments designed specifically for weight management, BPC-157 does not seem to: Reduce appetite Increase feelings of fullness Trigger fat burning Significantly increase calorie expenditure Instead, any potential weight-related benefits are generally believed to occur indirectly through improvements in recovery, mobility, and overall physical function
It is administered weekly via an injection pen into the belly, thigh, or upper arm
Both perspectives are valid
LDN, on the other hand, is often used for a longer duration
In rodent studies, GLP-1s caused thyroid tumors, including thyroid cancer